Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Harmony Biosciences Holdings (HRMY) Receivables - Net (2019 - 2025)

Harmony Biosciences Holdings' Receivables - Net history spans 7 years, with the latest figure at $96.8 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 16.56% year-over-year to $96.8 million; the TTM value through Dec 2025 reached $96.8 million, up 16.56%, while the annual FY2025 figure was $96.8 million, 16.56% up from the prior year.
  • Receivables - Net for Q4 2025 was $96.8 million at Harmony Biosciences Holdings, down from $100.7 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $106.0 million in Q1 2025 and bottomed at $23.6 million in Q1 2021.
  • The 5-year median for Receivables - Net is $65.5 million (2023), against an average of $65.1 million.
  • The largest annual shift saw Receivables - Net soared 103.39% in 2021 before it grew 11.81% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $34.8 million in 2021, then surged by 57.1% to $54.7 million in 2022, then skyrocketed by 35.44% to $74.1 million in 2023, then rose by 11.99% to $83.0 million in 2024, then increased by 16.56% to $96.8 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Receivables - Net are $96.8 million (Q4 2025), $100.7 million (Q3 2025), and $93.0 million (Q2 2025).